0.609
price up icon3.69%   0.0217
after-market 시간 외 거래: .61 0.001 +0.16%
loading

Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스

pulisher
Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Purchases Shares of 25,259 ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) - Defense World

Apr 02, 2025
pulisher
Mar 27, 2025

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

ZyVersa Slashes Annual Losses by 90% While Pushing Forward With Crucial Kidney Disease Drug Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World

Mar 27, 2025
pulisher
Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

ZVSA stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World

Mar 24, 2025
pulisher
Mar 19, 2025

ZyVersa’s IC 100 shows promise in OAC treatment study By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

ZyVersa’s IC 100 shows promise in OAC treatment study - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ... - The Bakersfield Californian

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Breakthrough: New Drug Could Transform 50% Survival Rate in Obesity Heart Disease - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 14, 2025

Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6% - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

ZVSA stock touches 52-week low at $0.8 amid sharp annual decline - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

ZVSA stock touches 52-week low at $0.8 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

ZyVersa’s Alzheimer’s treatment shows promise in studies By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa’s Alzheimer’s treatment shows promise in studies - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model - The Manila Times

Mar 12, 2025
pulisher
Mar 12, 2025

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Breakthrough: ZyVersa's New Alzheimer's Treatment Targets Brain Inflammation With Promising Results - Stock Titan

Mar 12, 2025
pulisher
Mar 07, 2025

ZyVersa secures $2 million in funding for drug development By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 06, 2025

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

ZyVersa Therapeutics announces pricing of $2M private placement - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

ZyVersa secures $2 million in funding for drug development - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Healthcare Fund Backs ZyVersa With $2M Investment: Key Terms Revealed - StockTitan

Mar 06, 2025
pulisher
Mar 05, 2025

ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

ZVSA stock plunges to 52-week low, touches $0.94 amid market challenges By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Wall Street Set to Open on Flat Note Wednesday as Investors Look for Signs of Tariff Relief - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

ZyVersa’s IC 100 shows promise in heart failure treatment By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Di - The Manila Times

Mar 05, 2025
pulisher
Mar 05, 2025

ZyVersa’s IC 100 shows promise in heart failure treatment - Investing.com

Mar 05, 2025
pulisher
Feb 28, 2025

New Biotech Stocks at Investorideas.com - Investorideas.com newswire

Feb 28, 2025
pulisher
Feb 24, 2025

Major Gestational Diabetes Market Trend 2025-2034: Advancements In Diagnostic Solutions For Early Detection... - WhaTech

Feb 24, 2025
pulisher
Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Online

Feb 13, 2025
pulisher
Feb 10, 2025

Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga

Feb 10, 2025
pulisher
Feb 07, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga

Feb 07, 2025
pulisher
Feb 05, 2025

Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart

Feb 05, 2025
pulisher
Jan 31, 2025

Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 1,291.0% - Defense World

Jan 31, 2025
pulisher
Jan 15, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Decrease in Short Interest - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Blaize Debuts on NASDAQ: First AI IPO of 2025 Hits $1.2B Valuation in Historic SPAC Deal - StockTitan

Jan 14, 2025
pulisher
Jan 08, 2025

2024 Research Report: Global Celiac Disease Treatment - GlobeNewswire

Jan 08, 2025
$67.50
price down icon 1.20%
$73.33
price down icon 0.15%
$31.78
price up icon 1.60%
$18.90
price down icon 7.62%
$92.01
price down icon 1.40%
biotechnology ONC
$264.48
price down icon 3.75%
자본화:     |  볼륨(24시간):